* Q2 net EPS $0.22, non-GAAP EPS $0.79
* Raises 2009 EPS outlook to $2.70 to $2.80
* Shares rise 8 percent
LOS ANGELES, July 28 (Reuters) - Life Technologies Corp (LIFE.O), a maker of tools and equipment used in genetic testing and stem cell research, on Tuesday reported a second-quarter profit that beat Wall Street estimates, helped by integration-related combinations and better pricing.
The company, which was created by the merger of Invitrogen and Applied Biosystems, also raised its outlook for full-year earnings and shares rose 8 percent in after-market trading.
Excluding items, such as 42 cents per share for merger and integration-related charges, the company earned 79 cents per share, topping the average analyst estimate of 66 cents per share, according to Reuters Estimates.
The Carlsbad, California-based company posted a net profit of 22 cents per share, compared with 55 cents a year ago.
Non-GAAP revenue rose 2 percent to $839 million.
Life said it now expects mid single-digit organic revenue growth for the full year with earnings of $2.70 to $2.80 per share, excluding items. The company had previously forecast full-year earnings of $2.40 to $2.55 per share.
Life Technologies shares rose to $46.40 in after hours trading from their Nasdaq close at $42.91.